YDES YD Bio Ltd

4.560USD-5.98%Mkt Cap: 322.99M USDP/E: —

YD Bio Limited, a biopharmaceutical company, focuses on regulated diagnostics, life science clinical services, and healthcare product commercialization in the United States and Taiwan. The company offers eye disease trea…

Insiders, last 90 days3 buys
Institutional holders11 on file

Key Statistics

Company
Market Cap322.99M USD
Enterprise Value340.93M USD
Revenue (TTM)1.24M USD
Gross Profit167.41K USD
Net Income (TTM)-8.31M USD
Revenue/Share0.02 USD
Last Price4.560 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees13
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)—
PEG—
EV/EBITDA-53.76
EV/Revenue275.10
P/S260.62
P/B72.38
EPS (TTM)-0.04 USD
EPS (Forward)—
52W Range
1.70020% of range15.72
52W High15.72 USD
52W Low1.700 USD
Profitability
Gross Margin28.05%
Oper. Margin-528.72%
EBITDA Margin0.00%
Profit Margin-1392.61%
ROE291.05%
ROA-60.32%
ROIC—
ROCE-43.41%
Growth
Revenue Growth314.90%
Earnings Growth—
Cash Flow & Leverage
Operating CF-6.60M USD
CapEx (TTM)1.44M USD
FCF Margin—
FCF Yield—
Net Debt-2.66M USD
Net Debt/EBITDA0.42
Net Debt/FCF—
Balance Sheet
Debt/Equity-0.00
Current Ratio5.23
Quick Ratio2.70
Book Value/Sh0.06 USD
Cash/Share0.04 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.70.83M
Float16.19M
Insiders80.18%
Institutions0.62%
Short Interest
Short Ratio1.1d
Short % Float1.14%
Short % Out.0.26%
Shares Short187.41K
Short (prev mo.)177.33K
Technical
SMA 505.539 (-17.7%)
SMA 2005.201 (-12.3%)
Beta-0.13
S&P 52W Chg12.08%
Avg Vol (30d)96.67K
Avg Vol (10d)77.33K
Technical Indicators
RSI (14)40.6
MACD-0.2485
MACD Signal-0.0337
MACD Hist.-0.2148
BB Upper7.301 USD
BB Middle5.739 USD
BB Lower4.176 USD
BB Width54.46%
ATR (14)0.8173 USD
Vol Ratio (20d)0.51x

About YD Bio (NASDAQ: YDES)

›

YD Bio (NASDAQ: YDES) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 13 employees.

The shares were at 4.560 USD on 19 November 2026, down 53.3% over 52 weeks. Its 52-week range is 1.700 USD to 15.72 USD: the price is 71.0% below the high and 168.2% above the low.

Its market capitalisation is 322.99M USD.

YD Bio reports return on equity of 291.0% and revenue up 314.9% year over year.

It holds more cash than debt, a net cash position of 2.66M USD. Its Piotroski F-score is 3 out of 9, a weak reading of its financial health.